Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trial
Arthritis & Rheumatism2012Vol. 65(2), pp. 314–324
Citations Over TimeTop 1% of 2012 papers
Chester V. Oddis, Ann M. Reed, Rohit Aggarwal, Lisa G. Rider, Dana P. Ascherman, Marc C. Levesque, Richard J. Barohn, Brian M. Feldman, Michael O. Harris‐Love, Diane Koontz, Noreen Fertig, Stephanie Kelley, Sherrie L. Pryber, Frederick W. Miller, Howard E. Rockette, and the RIM Study Group
Abstract
Although there were no significant differences in the 2 treatment arms for the primary and secondary end points, 83% of adult and juvenile myositis patients with refractory disease met the DOI. The role of B cell-depleting therapies in myositis warrants further study, with consideration for a different trial design.
Related Papers
- → Severe Perturbations of the Blood T Cell Repertoire in Polymyositis, But Not Dermatomyositis Patients(2001)85 cited
- → Rheumatic manifestations of polymyositis and dermatomyositis(1959)59 cited
- [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].(2000)
- [Pathogenesis of polymyositis and dermatomyositis].(2012)
- → SP0131 How to treat(2012)